CTOs on the Move

Ensight Plus

www.ensightplus.com

 
At Ensight Plus, we are dedicated to empowering businesses in the utility industry to achieve remarkable success. We leverage our extensive experience to customize technology solutions that seamlessly align with each clients unique requirements. We believe that a one-size-fits-all approach is ineffective, so we tailor our offerings to their specific business objectives. Our commitment extends to genuinely understanding our clients needs and goals. We are passionate and committed to their success and strive to provide exceptional customer service from the initial engagement to the provision of long-term support.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

nurse brokers inc

nurse brokers inc is a Laughlin, NV-based company in the Business Services sector.

IntelliHost

Described as a vacation rental investors best friend, IntelliHost gives hosts their unique listings Airbnb search metric data to improve their listings and make thousands of dollars more with the same properties.

Tri-S Controls Inc

Tri-S Controls Inc is a Valley City, OH-based company in the Business Services sector.

Axis Environmental

Axis Environmental LLC is a Reno, NV-based company in the Business Services sector.

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.